⌘K
Loading ticker…
Vericel Corporation · Healthcare · Pharmaceutical Products
As of 2026-06-26, Vericel Corporation (VCEL) has a 3-month relative strength percentile of 89 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 61. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 4.6%, relative volume 3.69×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
3m RS is 89, Market Stance is mixed at 47, A/D rating A
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
VCEL is in a stage 2 uptrend, week 1. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 28.2% / 29.6%.
Strong relative strength with attention running hot versus its own recent norm. The trend is intact but well-noticed; elevated retail attention has historically been associated with softer forward returns. Context, not a call.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
VCEL is held by 7 ETFs as of Mar 2026. Top owner: IJR at 0.11% weight, $98M notional. Top 3 carry $189M.
Top 7 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| IJRiShares Core S&P Small-Cap ETF | 0.11% | $98M |
| VTIVanguard Total Stock Market ETF | 0.00% | $52M |
| IWMiShares Russell 2000 ETF | 0.06% | $40M |
| XBIState Street SPDR S&P Biotech ETF | 0.48% | $36M |
| VXFVanguard Extended Market ETF | 0.02% | $18M |
| IWOiShares Russell 2000 Growth ETF | 0.11% | $13M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.00% | $2M |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | VCEL Jan avg: 7.88% median: 5.45% win: 75% σ: 8.98% n: 4 2022-04-12 → 2026-05-29 | VCEL Feb avg: 0.94% median: 2.72% win: 50% σ: 10.08% n: 4 2022-04-12 → 2026-05-29 | VCEL Mar avg: -3.14% median: -6.71% win: 25% σ: 12.00% n: 4 2022-04-12 → 2026-05-29 | VCEL Apr avg: -6.55% median: -11.82% win: 40% σ: 13.49% n: 5 2022-04-12 → 2026-05-29 | VCEL May avg: 1.15% median: 1.94% win: 60% σ: 5.61% n: 5 2022-04-12 → 2026-05-29 | VCEL Jun avg: 2.23% median: -0.39% win: 50% σ: 10.71% n: 4 2022-04-12 → 2026-05-29 (current) | VCEL Jul avg: 4.27% median: 2.86% win: 50% σ: 20.19% n: 4 2022-04-12 → 2026-05-29 | VCEL Aug avg: -6.41% median: -3.18% win: 50% σ: 12.59% n: 4 2022-04-12 → 2026-05-29 | VCEL Sep avg: -9.14% median: -10.23% win: 25% σ: 8.79% n: 4 2022-04-12 → 2026-05-29 | VCEL Oct avg: 9.12% median: 8.18% win: 100% σ: 5.54% n: 4 2022-04-12 → 2026-05-29 | VCEL Nov avg: 8.19% median: 7.91% win: 75% σ: 20.03% n: 4 2022-04-12 → 2026-05-29 | VCEL Dec avg: -0.13% median: -2.68% win: 50% σ: 11.23% n: 4 2022-04-12 → 2026-05-29 |